Study Name: LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment
16 locations found
- 1200.131.00171 Boehringer Ingelheim Investigational Site
Location: Little Rock, Alaska
- 1200.131.00178 Boehringer Ingelheim Investigational Site
Location: Los Angeles, California
- 1200.131.00181 Boehringer Ingelheim Investigational Site
Location: Orange, California
- 1200.131.00185 Boehringer Ingelheim Investigational Site
Location: New Haven, Connecticut
- 1200.131.00191 Boehringer Ingelheim Investigational Site
Location: Harvey, Illinois
- 1200.131.00187 Boehringer Ingelheim Investigational Site
Location: New Orleans, Louisiana
- 1200.131.00173 Boehringer Ingelheim Investigational Site
Location: Baltimore, Maryland
- 1200.131.00176 Boehringer Ingelheim Investigational Site
Location: Boston, Massachusetts
- 1200.131.00190 Boehringer Ingelheim Investigational Site
Location: Boston, Massachusetts
- 1200.131.00182 Boehringer Ingelheim Investigational Site
Location: Omaha, Nebraska
- 1200.131.00175 Boehringer Ingelheim Investigational Site
Location: Lebanon, New Hampshire
- 1200.131.00188 Boehringer Ingelheim Investigational Site
Location: Bronx, New York
- 1200.131.00179 Boehringer Ingelheim Investigational Site
Location: Stony Brook, New York
- 1200.131.00172 Boehringer Ingelheim Investigational Site
Location: Philadelphia, Pennsylvania
- 1200.131.00184 Boehringer Ingelheim Investigational Site
Location: San Antonio, Texas
- 1200.131.00183 Boehringer Ingelheim Investigational Site
Location: Wenatchee, Washington
|